The Medicines and Healthcare products Regulatory Agency has issued a seasonal safety reminder for people taking prescription and over-the-counter medicines during warm weather. In a GOV.UK notice tied to its Summer-proof your health campaign, the UK regulator says some medicines can increase the risk of dehydration, reduce the body's ability to manage heat, or make skin more sensitive to sunlight. The notice does not alter prescribing rules. Its purpose is risk communication: patients, carers and front-line clinicians are being reminded that hotter conditions can change the practical safety profile of otherwise routine treatments.
According to the MHRA, one group of concern is medicines that affect fluid balance or temperature control. Diuretics, commonly used for blood pressure or heart conditions, can increase fluid loss. Some antidepressants and antipsychotics may interfere with temperature regulation, while beta blockers can reduce the body's response to heat stress. In practice, that means heat-related illness may begin with signs that are easy to overlook in community settings. The GOV.UK update points to dizziness, headache, unusual fatigue, confusion and reduced urination as warning signs that the body is struggling in the heat.
The regulator also highlights medicines associated with photosensitivity, where sun exposure can produce a quicker or more severe skin reaction than expected. The MHRA lists antibiotics including doxycycline and tetracycline, acne treatments such as isotretinoin and topical retinoids, and the antifungal voriconazole. The same warning extends to disease-modifying antirheumatic drugs including methotrexate and azathioprine, which are used for conditions such as rheumatoid arthritis, psoriatic arthritis and lupus. The agency also notes a very low risk of a lupus-like skin reaction linked to proton pump inhibitors after sun exposure, and says anti-inflammatory painkillers including ibuprofen and naproxen may increase sun sensitivity.
The MHRA's practical advice is straightforward. People are being asked to check the patient information leaflet that comes with their medicine, review any advice on hydration or sun exposure, and use standard protective steps such as drinking enough fluid, avoiding the strongest sun in the middle of the day, and wearing sunscreen and protective clothing. The framing matters because it treats summer safety as a medicines issue, not only a weather issue. For pharmacies, general practice and carers, the message is that hot-weather advice may need to be tailored to the treatment a person is taking, rather than given as a generic warning.
The regulator is explicit that prescribed treatment should not be stopped without professional advice. Anyone unsure whether a medicine could be affected by heat or sunlight is being told to speak to a pharmacist or GP before making changes. That is an important safeguard. Seasonal public messaging can reduce avoidable harm only if it does not create uncertainty about adherence, particularly for long-term conditions. The MHRA therefore keeps two points together: warmer weather can change risk, but treatment decisions still require clinical oversight.
For suspected side effects, the GOV.UK notice directs patients first to their doctor, pharmacist or nurse, and then to the MHRA Yellow Card scheme, which collects reports to support medicines safety monitoring. The agency adds that people can now use NHS login to create or access a Yellow Card account. As a regulatory communication, the update is a targeted safety notice. It does not create a new reporting duty or prescribing requirement, but it does show how the MHRA uses seasonal campaigns to reinforce existing safety information and channel suspected adverse effects into the formal reporting system.